Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model

被引:51
作者
Ahmed, F
Ings, SJ
Pizzey, AR
Blundell, MP
Thrasher, AJ
T Ye, H
Fahey, A
Linch, DC
Yong, KL
机构
[1] UCL Royal Free & Univ Coll Med Sch, Dept Haematol, London WC1E 6HX, England
[2] UCL Royal Free & Univ Coll Med Sch, Dept Histopathol, London WC1E 6HX, England
[3] Inst Child Hlth, Mol Immunol Unit, London, England
[4] Guangxi Med Univ, Dept Pathol, Guangxi, Peoples R China
关键词
D O I
10.1182/blood-2003-06-1770
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The reduced engraftment potential of hematopoietic stem/progenitor cells (HSPCs) after exposure to cytokines may be related to the impaired homing ability of actively cycling cells. We tested this hypothesis by quantifying the short-term homing of human adult Cb34(+) cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals. We show that the loss of engraftment ability of cytokine-aciivated CD34(+) cells is associated with a reduction in homing of colony-forming cells (CFCs) to bone marrow (BM) at 24 hours after transplantation (from median 2.6% [range, 1.9%-6.1%] to 0.3% [0.0%6-0.7%]; n = 3; P < .01), coincident with an increase in CFC accumulation in the lungs (P < .01). Impaired BM homing of cytokine-activated cells was not restored by using sorted cells in G(0)G(1) or by inducing cell cycle arrest at the G(1)/S border. Blocking Fas ligation in vivo did not increase the BM homing of cultured cells. Finally, we tested cytokine combinations or culture conditions previously reported to restore the engraftment of cultured cells but did not find that any of these was able to reverse the changes in homing behavior of cytokine-exposed cells. We suggest that these changes in homing and, as a consequence, engraftment result from the increased migratory capacity of infused activated cells, leading to the loss of selectivity of the homing process. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:2079 / 2087
页数:9
相关论文
共 41 条
[1]   Quality of repopulation in nonobese diabetic severe combined immunodeficient mice engrafted with expanded cord blood CD34+ cells [J].
Blundell, MP ;
Demaison, C ;
Brouns, G ;
Goldman, JP ;
Gaspar, HB ;
Kinnon, C ;
Thrasher, AJ ;
Lazzari, L ;
Sirchia, G .
BLOOD, 1999, 94 (09) :3269-3270
[2]   Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice [J].
Cashman, J ;
Clark-Lewis, I ;
Eaves, A ;
Eaves, C .
BLOOD, 2002, 99 (03) :792-799
[3]   QUANTITATIVE STUDIES OF BLOOD AND BONE MARROW NEUTROPHILS IN NORMAL MICE [J].
CHERVENICK, PA ;
BOGGS, DR ;
MARSH, JC ;
CARTWRIGHT, GE ;
WINTROBE, MM .
AMERICAN JOURNAL OF PHYSIOLOGY, 1968, 215 (02) :353-+
[4]   Dissociation between stem cell phenotype and NOD/SCID repopulating activity in human peripheral blood CD34+ cells after ex vivo expansion [J].
Danet, GH ;
Lee, HW ;
Luongo, JL ;
Simon, MC ;
Bonnet, DA .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (12) :1465-1473
[5]   FLT3 ligand preserves the ability of human CD34(+) progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction [J].
Dao, MA ;
Hannum, CH ;
Kohn, DB ;
Nolta, JA .
BLOOD, 1997, 89 (02) :446-456
[6]   A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukemia virus-pseudotyped retroviral vector [J].
Demaison, C ;
Brouns, G ;
Blundell, MP ;
Goldman, JP ;
Levinsky, RJ ;
Grez, M ;
Kinnon, C ;
Thrasher, AJ .
HUMAN GENE THERAPY, 2000, 11 (01) :91-100
[7]  
Dorrell C, 2000, BLOOD, V95, P102
[8]   Increased binding and defective migration across fibronectin of cycling hematopoietic progenitor cells [J].
Giet, O ;
Van Bockstaele, DR ;
Di Stefano, I ;
Huygen, S ;
Greimers, R ;
Beguin, Y ;
Gothot, A .
BLOOD, 2002, 99 (06) :2023-2031
[9]   Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G2/M transit and do not reenter G0 [J].
Glimm, H ;
Oh, IL ;
Eaves, CJ .
BLOOD, 2000, 96 (13) :4185-4193
[10]   Ex vivo treatment of proliferating human cord blood stem cells with stroma-derived factor-1 enhances their ability to engraft NOD/SCID mice [J].
Glimm, H ;
Tang, P ;
Clark-Lewis, I ;
von Kalle, C ;
Eaves, C .
BLOOD, 2002, 99 (09) :3454-3457